Drug Type Cell therapy |
Synonyms IxCell PB-ZRAK |
Target |
Action antagonists |
Mechanism NKG2D antagonists(NKG2-D type II integral membrane protein antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Hepatocellular Carcinoma | IND Approval | China | 20 May 2026 |





